

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Teva Pharmaceuticals USA, Inc. (TEVA USA) is initiating a nationwide recall of the above referenced drug products to the **RETAIL LEVEL**. The products in this recall were distributed to TEVA USA direct customers under the Teva Pharmaceuticals USA, Inc. label. The reason for the recall is there is a possibility of discolored tablets (shades of blue) mixed in with the white inert ‘reminder’ tablets. The discolored reminder tablets may contain trace amounts of estradiol active pharmaceutical ingredient (API). The inert ‘reminder’ tablets should contain no API. Test samples have shown that the trace quantities of estradiol API in the discolored ‘reminder’ tablets are at or below 10% of the established Acceptable Daily Exposure (ADE) limit of the estradiol API of 2.0 mcg/tablet. The trace amounts of estradiol API in the reminder tablets of the affected lots are not expected to cause additional side effects or adverse health consequences.

Nortrel® and Nortrel® 7/7/7 (norethindrone and ethinyl estradiol tablets USP)

Label	Lot #	Exp. Date	Strength	Size	Carton NDC	Blister NDC
Nortrel®	100042978	07/2024	0.5 mg /0.035 mg	3 Blister Cards, 28 Tablets Each	0555-9008-67	0555-9008-79
			0.5 mg /0.035 mg	6 Blister Cards,		
Nortrel®7/7/7	100040731	07/2024	0.75 mg /0.035 mg	28 Tablets Each	0555-9012-58	0555-9012-79
			1 mg /0.035 mg			